Legochem Biosciences, Inc.

Novimmune Sa

Abl Bio Inc.

Hyun Min Ryu

Yong Zu Kim

Ho Young Song

Jeiwook Chae

Sung Min Kim

Hyoung Rae Kim

Ji Hye Oh

Nicolas Fischer

Ju Young Lee

Bora Lee

Juhee Kim

Yeong Soo Oh

Yun Hee Park

Yangsoon Lee

Kyung Eun Park

Byungje Sung

Dae Hyuck Kang

Kyungjin Park

Chang Sun Lee

Jinhyung Ahn

Donghoon Yeom

Jiseon Yoo

Yun-Hee Park

Daehae Song

Jaehyun Eom

Minji Park

Hyeun Joung Lee

JinWon Jung

Ju Yuel Baek

Young-Jae Yang

Nara Han

Ji-Na You

Youngeun Hong

Maureen Deehan

The present disclosure relates to antibody-drug conjugates (ADCs) wherein one or more active agents are conjugated to an anti-CD19 antibody through a linker. The linker may comprise a unit that covalently links active agents to the antibody. The disclosure further relates to monoclonal antibodies and antigen binding fragments, variants, multimeric versions, or bispecifics thereof that specifically bind CD19, as well as methods of making and using these anti-CD19 antibodies and antigen-binding fragments thereof in a variety of therapeutic, diagnostic and prophylactic indications.

Compositions and methods related to anti-CD19 antibody drug conjugates

The present invention relates to new antibody-drug conjugates (ADCs) targeting ROR1, active metabolites of such ADCs, methods for preparation of such ADCs, uses for such ADCs in treatment and/or prevention of illnesses, and uses for such ADCs in production of drugs for treatment and/or prevention of diseases, more specifically diseases associated with over-expression of ROR1, for example cancer. More specifically, the present invention relates to an antibody-drug conjugate comprising an antibody that binds to ROR1 or an antigen-binding fragment thereof, and a pharmaceutical composition comprising the same.

Antibody-drug conjugate comprising antibody against human ROR1 and use for the same

Growing community of inventors

Daejeon, South Korea

Hyun Min Ryu